Drugs / F-02-2-Na
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07346027 | Jul → Aug 2026 overdue | — | Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07324434 | Dec 2025 → Oct 2026 expected | — | Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-02-2-Na | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07346027 ↗ |
| Route | Oral | “single oral administration of F-02-2-Na tablets” NCT07324434 ↗ |